 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
Enrollment open, CAR T-Cell Therapy: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer (clinicaltrials.gov) - Jul 10, 2023
P1, N=24, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting
- || iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
New P1 trial, CAR T-Cell Therapy: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer (clinicaltrials.gov) - Nov 17, 2022
P1, N=24, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov) - Apr 11, 2022
P1, N=18, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Sep 2038 --> Jun 2039 | Trial primary completion date: Sep 2023 --> Jun 2024
- | iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov) - Apr 22, 2021
P1, N=18, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial completion date: Sep 2038 --> Jun 2039 | Trial primary completion date: Sep 2023 --> Jun 2024 Trial completion date: Jun 2039 --> Sep 2038 | Trial primary completion date: Jun 2024 --> Sep 2023
- | iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov) - Dec 20, 2019
P1, N=18, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial completion date: Jun 2039 --> Sep 2038 | Trial primary completion date: Jun 2024 --> Sep 2023 Trial completion date: May 2036 --> Jun 2039 | Trial primary completion date: May 2021 --> Jun 2024
- | iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
Enrollment open, CAR T-Cell Therapy: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov) - Apr 4, 2019
P1, N=18, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial completion date: May 2036 --> Jun 2039 | Trial primary completion date: May 2021 --> Jun 2024 Not yet recruiting --> Recruiting
- | iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
New P1 trial, CAR T-Cell Therapy: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov) - Oct 25, 2018
P1, N=18, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center